Interdisciplinary working groups of expert scientists review the published studies and evaluate the weight of the evidence that an agent can increase the risk of cancer. The principles, procedures, and scientific criteria that guide the evaluations are described in the Preamble to the IARC Monographs.
Since 1971, more than 900 agents have been evaluated, of which more than 400 have been identified as carcinogenic, probably carcinogenic, or possibly carcinogenic to humans.
Call for nominations of agents for review in future IARC Monographs
11 May 2015
IARC encourages the general public, the scientific community, national health agencies, and other organizations, to
nominate agents for review in future IARC Monographs. For details, please see Information on nominations.
Meeting 115: Some Industrial Chemicals
31 March 2015
Meeting 115 on "Some Industrial Chemicals" is announced. For more information, please see Upcoming Meetings.
Volume 108: Some Drugs and Herbal Products
23 March 2015
We are pleased to announce that the Monographs on Pioglitazone and rosiglitazone, and Digoxin, are now available online. The remaining Monographs will be published subsequently.
25 June 2012 Volume 100 compiles information on tumour sites and mechanisms of carcinogenesis. About half of the agents classified in Group 1 were last reviewed more than 20 years ago, before mechanistic studies became prominent in evaluations of carcinogenicity. In addition, more recent epidemiological studies and animal cancer bioassays have demonstrated that many cancer hazards reported in earlier studies were later observed in other organs or through different exposure scenarios. Available at WHO Press